Results 201 to 210 of about 2,872,365 (306)

Association between thyroidea function and opioid agonist therapy: a prospective cohort study from Norway. [PDF]

J Endocr Soc
Heldal AT, Vold JH, Viste K, Chalabianloo F, Mellgren G, Johansson KA, Fadnes LT.   +6 more
europepmc   +1 more source

Phloroglucinol inhibits human ureteral contractions via activation of cAMP‐PKA pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Phloroglucinol is used to treat renal colic, especially when non‐steroidal anti‐inflammatory drugs are contraindicated. This study aimed to clarify its mechanism by examining effects on human ureteral contractility and underlying signalling pathways. Experimental Approach Urinary levels of neurokinin A (NKA), substance P
Hanwen Liu, Ruize Xu, Zihan Guan, Lei Liu, Guangda Lv, Weibo Chen, Jiliang Wen, Jianing Liu, Jieke Yan, Fangxin Gong, Pan Xiao, Xiulin Zhang, Lei Zhang   +12 more
wiley   +1 more source

Policy changes in opioid agonist therapy and impacts on HIV and hepatitis C prevention in Canadian federal prisons. [PDF]

Lancet Reg Health Am
Kronfli N, Madden LM, Stoové M, Price O, Altice FL.   +4 more
europepmc   +1 more source

Positive modulation of glucagon‐like peptide 1 (GLP‐1) receptor by endogenous haemorphins with implications in glucose metabolism and diabetes

British Journal of Pharmacology, EarlyView.
Haemorphins act on GLP‐1 receptor (GLP‐1R) activity and signalling in a positive allosteric manner. This leads to potentiated GLP‐1‐mediated activity and signalling, as well as insulin synthesis, which may have implications for glucose metabolism and, thereby, diabetes and obesity. (The graph was created in BioRender.com).
Farheen Badrealam Khan, Rwdah Mohamed Alameri, Yasir S. Raouf, Damien Maurel, Naiem Ahmad Wani, Anatoliy Shmygol, Irfa Anwar, Heng B. See, Elizabeth K. M. Johnstone, Elodie Dupuis, Eric Trinquet, Kevin D. G. Pfleger, Emilia Oueis, Mohammed Akli Ayoub   +13 more
wiley   +1 more source

Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis. [PDF]

Front Med (Lausanne)
Muñoz-Violant S, Spencer S, Gooderham E, Narayan S, Nosyk B, McCracken RK, Hedden L.   +6 more
europepmc   +1 more source

Agonist activity of N-Desmethylclozapine, a major clozapine metabolite, at delta opioid receptors.

, 2007
In the present study we report that N-desmethylclozapine (NDMC), a pharmacologically active metabolite of the atypical antipsychotic clozapine (CLOZ), acts as a selective and efficacious agonist at ð-opioid receptors.
DEDONI, SIMONA, ONALI, PIER LUIGI, OLIANAS, MARIA CONCETTA, Garau L   +3 more
core  

GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

British Journal of Pharmacology, EarlyView.
Background and Purpose Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy ...
Katarina Sićović, Katarina Nastić, Miroslav Dinić, Emilija Brdarić, Uroš Pecikoza, Maja Tomić, Ana Micov   +6 more
wiley   +1 more source

Treatment preferences of patients receiving opioid agonist therapy in spain: a discrete choice experiment. [PDF]

Addict Behav Rep
Dorado García ML, Alonso Ganuza Z, Henche Ruíz AI, Marcos Flores A, Orengo Caus T, Palma Álvarez RF, Rodríguez Cejas MA, Sánchez Máñez A, Vega Astudillo P, Sucunza Guibert D, Gómez-Barrera M, Yébenes Cortés M, Crespo Portero A.   +12 more
europepmc   +1 more source

Evaluating comparative effect of non-pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta-analysis. [PDF]

Addiction
Lv B, Zhang YX, Tao QF, Lin L, Li XY, Chen BZ, Zheng H.   +6 more
europepmc   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan   +4 more
wiley   +1 more source